Median progression-free survival was @ months ( @ % CI @-@ ) in the group assigned to chlorambucil plus ofatumumab compared with @ months ( @-@ ) in the group assigned to chlorambucil only ( hazard ratio @ , @ % CI @-@ ; p < @ ) .